Cadrenal Therapeutics, Inc. (CVKD) Price & Analysis

Compare

409 Followers

CVKD Stock Chart & Stats

$12.92

-$1.27(-7.12%)

At close: Jan 08 4:00 PM EST

$12.92

-$1.27(-7.12%)

Day’s Range― - ―

52-Week Range$6.75 - $22.90

Previous CloseN/A

Volume16.20K

Average Volume (3M)61.21K

Market Cap

$17.33M

Enterprise Value$24.41M

Total Cash (Recent Filing)$3.86M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.18

Next Earnings

Mar 18, 2026

EPS Estimate

-1.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.31

Shares Outstanding2,338,127

10 Day Avg. Volume121,677

30 Day Avg. Volume61,208

Financial Highlights & Ratios

PEG Ratio0.18

Price to Book (P/B)2.38

Price to Sales (P/S)0.00

P/FCF Ratio-2.40

Enterprise Value/Market Cap1.41

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.12K

Enterprise Value/Ebitda-1.69

Forecast

1Y Price Target

$45.00

Price Target Upside248.30% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-7.19

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThis is seen as a significant development for Cadrenal that advances a second tecarfarin indication to clinical trials.

Efficacy And Patient OutcomesTecarfarin has shown improvements in efficacy and the ability to maintain the patient within their target blood clotting ranges, potentially reducing hospitalization rates, morbidity, and mortality.

PartnershipsCadrenal announced a development agreement with Abbott to develop Tecarfarin in patients with Abbott’s HeartMate3 LVAD.

Bears Say

Cadrenal Therapeutics, Inc. News

Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia

Cadrenal Therapeutics (CVKD) acquired VLX-1005 and related 12-lipoxygenase assets from Veralox Therapeutics. The acquisition adds a late-stage, first-in-class...

17d ago

CVKD

Cadrenal Therapeutics appoints Lee Golden to board of directors

Cadrenal Therapeutics (CVKD) announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately....

27d ago

CVKD

PTCT

Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has provided an announcement. On December 23, 2025, Cadrenal Therapeutics, Inc. filed...

5d ago

CVKD

Cadrenal Therapeutics Announces New Securities Purchase Agreement

Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. On December 15, 2025, Cadrenal Therapeutics, Inc. entered...

12d ago

CVKD

Cadrenal Therapeutics Acquires VLX-1005 from Veralox

An announcement from Cadrenal Therapeutics, Inc. ( ($CVKD) ) is now available. On December 10, 2025, Cadrenal Therapeutics...

17d ago

CVKD

Cadrenal Therapeutics Appoints Dr. Golden to Board

An update from Cadrenal Therapeutics, Inc. ( ($CVKD) ) is now available. On December 1, 2025, Cadrenal Therapeutics...

27d ago

CVKD

Cadrenal Therapeutics Announces New Stock Offering Program

The latest announcement is out from Cadrenal Therapeutics, Inc. ( ($CVKD) ). On November 18, 2025, Cadrenal Therapeutics,...

1M ago

CVKD

Cadrenal Therapeutics Reports Increased Losses Amid Strategic Expansion

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

CVKD

Cadrenal Therapeutics reports Q3 EPS ($1.31) vs ($2.18) last year

“We have uniquely positioned ourselves to address gaps in anticoagulation treatment of multiple indications through the development of...

2M ago

CVKD

Cadrenal Therapeutics Elects New Director at Meeting

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has shared an announcement. On September 24, 2025, Cadrenal Therapeutics, Inc. held...

3M ago

CVKD

Cadrenal Therapeutics Acquires eXIthera’s Assets for Growth

The latest announcement is out from Cadrenal Therapeutics, Inc. ( ($CVKD) ). On September 12, 2025, Cadrenal Therapeutics,...

3M ago

CVKD

Cadrenal announces acquisition of assets of eXIthera Pharmaceuticals

Cadrenal Therapeutics (CVKD) announced the acquisition of the assets of eXIthera Pharmaceuticals, including its proprietary portfolio of investigational...

3M ago

CVKD

Cadrenal Therapeutics Advances Tecarfarin Development

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has released its Q2 earnings. Here is a breakdown of the information...

5M ago

CVKD

Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)

“We continue to advance our goal of developing transformative therapeutics to address the gaps in current anticoagulation therapy...

5M ago

CVKD

CVKD FAQ

What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?

Cadrenal Therapeutics, Inc. lowest stock price was $6.75 and its highest was $22.90 in the past 12 months.

What is Cadrenal Therapeutics, Inc.’s market cap?

Cadrenal Therapeutics, Inc.’s market cap is $17.33M.

When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?

Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 79 days.

How were Cadrenal Therapeutics, Inc.’s earnings last quarter?

Cadrenal Therapeutics, Inc. released its earnings results on Nov 10, 2025. The company reported -$1.31 earnings per share for the quarter, beating the consensus estimate of -$1.55 by $0.24.

Is Cadrenal Therapeutics, Inc. overvalued?

According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cadrenal Therapeutics, Inc. pay dividends?

Cadrenal Therapeutics, Inc. does not currently pay dividends.

What is Cadrenal Therapeutics, Inc.’s EPS estimate?

Cadrenal Therapeutics, Inc.’s EPS estimate is -1.21.

How many shares outstanding does Cadrenal Therapeutics, Inc. have?

Cadrenal Therapeutics, Inc. has 2,338,127 shares outstanding.

What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?

Cadrenal Therapeutics, Inc. reported an EPS of -$1.31 in its last earnings report, beating expectations of -$1.55. Following the earnings report the stock price went down -3.13%.

Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?

Currently, no hedge funds are holding shares in CVKD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Cadrenal Therapeutics, Inc. (CVKD) Earnings & Revenues

Historic Earnings Reports

CVKD Stock 12 Month Forecast

Average Price Target

$45.00

▲(248.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","46":"$46","15.25":"$15.25","25.5":"$25.5","35.75":"$35.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,15.25,25.5,35.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.66,16.07076923076923,18.481538461538463,20.892307692307693,23.303076923076922,25.713846153846152,28.12461538461538,30.535384615384615,32.94615384615385,35.356923076923074,37.7676923076923,40.178461538461534,42.58923076923077,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.66,16.07076923076923,18.481538461538463,20.892307692307693,23.303076923076922,25.713846153846152,28.12461538461538,30.535384615384615,32.94615384615385,35.356923076923074,37.7676923076923,40.178461538461534,42.58923076923077,{"y":45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.66,16.07076923076923,18.481538461538463,20.892307692307693,23.303076923076922,25.713846153846152,28.12461538461538,30.535384615384615,32.94615384615385,35.356923076923074,37.7676923076923,40.178461538461534,42.58923076923077,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.28,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.82,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.44,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.19,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.49,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.46,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.5,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >